What are the possible causes of the small white erosions observed at a patent ileo‑colonic anastomosis in the proximal rectum?

Small White Erosions at Ileo-Colonic Anastomosis: Differential Diagnosis

The small white erosions with minimal erythema at your patent end-to-end ileo-colonic anastomosis most likely represent either postoperative Crohn's disease recurrence (Rutgeert's score i2a) or ischemic changes related to the surgical anastomosis itself, with the key distinction being whether these lesions require treatment or simply represent benign surgical sequelae.

Primary Diagnostic Considerations

1. Postoperative Crohn's Disease Recurrence

If this patient has a history of Crohn's disease (CD), these lesions are highly concerning for endoscopic recurrence. According to the 2024 AGA guidelines, lesions confined to the ileocolonic anastomosis are classified as Rutgeert's score i2a 1. This classification is critical because:

• Patients with i2a lesions have an intermediate prognosis
• The modified Rutgeert's score specifically differentiates anastomotic lesions (i2a) from neoterminal ileal involvement (i2b)
• This distinction guides therapeutic decisions about initiating or escalating immunosuppression

Critical caveat: The 2024 guidelines explicitly note that ulcers at the anastomosis can represent ischemic changes versus active inflammatory changes and thus do not necessarily require treatment 1. This is the most important clinical pitfall to avoid—not all anastomotic lesions represent active CD requiring escalation of therapy.

2. Ischemic/Surgical Changes

The guidelines emphasize that lesions from the anastomotic site could result from the surgical procedure itself rather than disease recurrence 1. These benign surgical sequelae include:

• Ischemic changes from anastomotic tension or compromised blood supply
• Suture line granulation tissue
• Focal mucosal injury from surgical manipulation

3. Anastomotic Ulcers (Non-IBD)

Research evidence describes anastomotic ulcers occurring at ileocolonic anastomoses in non-CD patients, presenting with iron deficiency anemia and occult blood loss 2. These can develop months to years after surgery (15 months to 28 years in one series) and may be related to:

• NSAID use
• Mechanical factors at the anastomosis
• Idiopathic causes

4. Nonspecific Inflammatory Changes

Studies document that non-specific inflammatory changes occur at anastomoses in 39% of asymptomatic patients, with focal surface ulceration seen in over half of these cases, sometimes persisting years after operation 3. This represents continued regenerative activity at the anastomotic site.

Diagnostic Algorithm

Step 1: Establish surgical history

• Was this surgery for Crohn's disease, ulcerative colitis, cancer, or other indication?
• Time interval since surgery (if <6 months, more likely surgical; if >6 months, consider CD recurrence)

Step 2: Assess lesion characteristics

• Confined to anastomosis only = i2a (if CD) or benign surgical changes
• Extending into neoterminal ileum = i2b (more concerning for active CD)
• Diffuse inflammation = i3-i4 (requires treatment)

Step 3: Obtain targeted biopsies

• Histology can differentiate acute inflammation, chronic inflammation, granulomas (CD), or nonspecific changes
• Most erosive/ulcerative lesions without surrounding inflammation are nonspecific (84% in one study) 4

Step 4: Correlate with clinical symptoms

• Asymptomatic patients with isolated anastomotic lesions may not require treatment
• Symptomatic patients (increased stool frequency, abdominal pain, bleeding) warrant consideration of active disease

Step 5: Medication review

• Discontinue NSAIDs immediately if being used 2
• NSAIDs are a well-documented cause of anastomotic ulceration

Management Approach

If Crohn's Disease Recurrence (i2a):

• Timing matters: Colonoscopy is recommended 6-12 months post-surgery where treatment decisions may be affected 5
• Selective immunosuppression adjusted for early recurrence leads to disease control in most patients 1
• However, isolated i2a lesions without neoterminal ileal involvement may represent ischemic changes not requiring treatment escalation

If Ischemic/Surgical Changes:

• Observation is appropriate for asymptomatic patients
• Follow-up colonoscopy in 3-6 months to assess for progression or resolution
• No specific therapy required

If NSAID-Related or Idiopathic:

• Discontinue all NSAIDs 2
• Supplement with oral iron if anemia present
• Reserve surgery only for life-threatening bleeding or refractory anemia 2

Key Clinical Pitfalls

1. Do not automatically assume all anastomotic lesions represent active CD requiring treatment escalation—the 2024 guidelines specifically warn against this 1

2. The Rutgeert's score was designed for end-to-end anastomoses 30 years ago and has limitations, particularly in distinguishing ischemic from inflammatory changes 1

3. Careful follow-up is required when symptoms or lesions do not improve, as some initially nonspecific lesions later declare themselves as CD 4

4. Biopsy results showing "nonspecific inflammation" do not exclude CD—84% of erosive/ulcerative colonic lesions are histologically nonspecific 4

5. Rectal bleeding at an anastomosis may represent cuffitis rather than pouchitis or anastomotic disease in patients with ileal pouches 6